<h2><strong>Biologics Market to Reach USD 506 Billion by 2030</strong></h2>
<p>According to Straits Research, the global <a href="https://straitsresearch.com/report/biologics-market">Biologics Market</a> size was valued at&nbsp;<strong>USD 343 Billion</strong>&nbsp;in 2021 and is projected to reach&nbsp;<strong>USD 506 Billion</strong>&nbsp;by 2030, growing at a CAGR of&nbsp;<strong>4%</strong>&nbsp;during the forecast period (2022&ndash;2030).</p>
<p><strong>Biologics Market Catalysts for Expansion</strong></p>
<p>The Biologics Market is experiencing significant growth due to several key factors. Advances in biotechnology and increased investment in research and development are driving innovation in biologic drugs. The rising prevalence of chronic diseases, such as cancer and autoimmune disorders, is also fueling demand for biologics. Additionally, the growing acceptance of personalized medicine and the development of biosimilars are contributing to market expansion.</p>
<p><strong>Biologics Market Segment Breakdown</strong></p>
<p>The Biologics Market is segmented based on various criteria:</p>
<ol>
<li>
<p><strong>By Source</strong></p>
<ul>
<li>Mammalian</li>
<li>Microbial</li>
</ul>
</li>
<li>
<p><strong>By Manufacturing</strong></p>
<ul>
<li>In-house</li>
<li>Outsourced</li>
</ul>
</li>
<li>
<p><strong>By Product</strong></p>
<ul>
<li>Monoclonal Antibodies</li>
<li>Vaccines</li>
<li>Recombinant Proteins</li>
<li>Antisense &amp; RNAi Therapeutics</li>
<li>Others</li>
</ul>
</li>
<li>
<p><strong>By Disease Category</strong></p>
<ul>
<li>Oncology</li>
<li>Infectious Diseases</li>
<li>Immunological Disorders</li>
<li>Cardiovascular Disorders</li>
<li>Hematological Disorders</li>
<li>Others</li>
</ul>
</li>
<li>
<p><strong>By Type</strong></p>
<ul>
<li>Tumor Necrosis Factor (TNF) Inhibitor</li>
<li>T-cell Inhibitor</li>
<li>Selective Co-stimulation Modulators</li>
<li>Interleukin-6 (IL-6) or Interleukin-17 Blocker</li>
<li>Interleukin-1 (IL-1) Blocker</li>
<li>B-cell Inhibitor</li>
</ul>
</li>
<li>
<p><strong>By Drug Class</strong></p>
<ul>
<li>Monoclonal Antibody</li>
<li>Recombinant Insulin</li>
<li>Vaccine</li>
<li>Blood Factor</li>
<li>Human Growth Hormone</li>
<li>Erythropoietin</li>
<li>Fusion Protein</li>
<li>Recombinant Enzyme</li>
<li>Interferon</li>
<li>Colony-stimulating Factor</li>
<li>Gene Therapy</li>
<li>Cell Therapy</li>
<li>Oligonucleotides</li>
<li>Peptide</li>
<li>Botulinum Toxin</li>
<li>Others</li>
</ul>
</li>
<li>
<p><strong>By Source</strong></p>
<ul>
<li>Microbial</li>
<li>Mammalian</li>
<li>Others</li>
</ul>
</li>
<li>
<p><strong>By Drug Type</strong></p>
<ul>
<li>Branded Drugs</li>
<li>Generic Drugs</li>
</ul>
</li>
<li>
<p><strong>By Mode of Purchase</strong></p>
<ul>
<li>Prescription Drugs</li>
<li>Over-the-counter (OTC) Drugs</li>
</ul>
</li>
<li>
<p><strong>By Dosage Form</strong></p>
<ul>
<li>Injection</li>
<li>Tablets</li>
<li>Others</li>
</ul>
</li>
<li>
<p><strong>By Route of Administration</strong></p>
<ul>
<li>Parenteral</li>
<li>Oral</li>
<li>Others</li>
</ul>
</li>
<li>
<p><strong>By End-Users</strong></p>
<ul>
<li>Hospitals</li>
<li>Specialty Clinics</li>
<li>Homecare</li>
<li>Others</li>
</ul>
</li>
<li>
<p><strong>By Distribution Channel</strong></p>
<ul>
<li>Hospital Pharmacy</li>
<li>Retail Pharmacy</li>
<li>Online Pharmacy</li>
<li>Others</li>
</ul>
</li>
</ol>
<p><strong>Download Free Sample Report with&nbsp;Complimentary Analyst Consultation : <a href="https://straitsresearch.com/report/biologics-market/request-sample">https://straitsresearch.com/report/biologics-market/request-sample</a><br /></strong></p>
<p><strong>Top Performing Companies</strong></p>
<p>Several companies are leading the charge in the Biologics Market, including:</p>
<ul>
<li>Bristol-Myers Squibb Company</li>
<li>Merck KGaA</li>
<li>Novartis AG</li>
<li>Novo Nordisk A/S</li>
<li>Pfizer Inc</li>
<li>Johnson &amp; Johnson Services Inc</li>
<li>Hoffmann La Roche Ltd</li>
</ul>
<p><strong>Biologics Market Emerging Prospects</strong></p>
<p>The future of the Biologics Market looks promising with the emergence of new therapeutic areas and the development of novel biologic drugs. The increasing focus on rare diseases and orphan drugs is expected to open new avenues for market growth. Additionally, advancements in gene therapy and cell therapy are likely to revolutionize the treatment landscape.</p>
<p><strong>Biologics Market Industry Movements</strong></p>
<p>The industry is witnessing significant movements, including mergers and acquisitions, strategic collaborations, and partnerships. These activities are aimed at enhancing product portfolios, expanding geographic reach, and strengthening market positions. Companies are also investing in advanced manufacturing technologies to improve production efficiency and reduce costs.</p>
<p><strong>Biologics Market Geographic Analysis</strong></p>
<p>Geographically, North America holds the largest share of the Biologics Market, followed by Europe and the Asia-Pacific region. The presence of major pharmaceutical companies, robust healthcare infrastructure, and high healthcare expenditure are driving market growth in these regions. The Asia-Pacific region is expected to witness the highest growth rate due to increasing healthcare investments, rising patient awareness, and improving healthcare facilities.</p>
<p><strong>Biologics Market Data Insights</strong></p>
<p>The Biologics Market is characterized by a high level of innovation and a strong pipeline of new products. Continuous advancements in biotechnology and the increasing adoption of biologics in clinical practice are expected to drive market growth. The market is also benefiting from favorable regulatory policies and government initiatives aimed at promoting the development and use of biologic drugs.</p>
<p><strong>Contact Us</strong><br /><strong>Email:</strong>&nbsp;<a>sales@straitsresearch.com</a><br /><strong>Phone:</strong>&nbsp;+1 646 905 0080 (US), +91 8087085354 (India), +44 203 695 0070 (UK)</p>
